Synonyms: EIDD-2801 | EIDD2801 | MK-4482 | MK4482
Compound class:
Synthetic organic
Comment: Molnupiravir (EIDD-2801, MK-4482) is a clinical stage, oral, broad-spectrum antiviral drug [1,3]. The proposed INN molnupiravir was released by the WHO in a special release to cover COVID-related therapeutics in October 2020 (Proposed INN: List 124- COVID-19). Chemically molnupiravir it is the isopropylester prodrug of the ribonucleoside analogue β-D-N4-hydroxycytidine (EIDD-1931, or N-hydroxycytidine) [4-5]. EIDD-2801 was originally designed by Emory University scientists to inhibit replication of influenza virus. It has subsequently been tested for activity against other RNA viruses, including pandemic SARS-CoV-2, SARS-CoV and MERS-CoV [6]. EIDD-2801 is being progressed for COVID-19 in a collaboration between Ridgeback Biotherapeutics and Merck.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Synonyms ![]() |
EIDD-2801 | EIDD2801 | MK-4482 | MK4482 |
Database Links ![]() |
|
CAS Registry No. | 2349386-89-4 (source: WHO INN record) |
DrugCentral Ligand | 5377 |
GtoPdb PubChem SID | 405067330 |
PubChem CID | 145996610 |
Search Google for chemical match using the InChIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
Search Google for chemicals with the same backbone | HTNPEHXGEKVIHG |
Search UniChem for chemical match using the InChIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
Search UniChem for chemicals with the same backbone | HTNPEHXGEKVIHG |